Compare Gerdau S.A. Common Stock (GGB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Natera Inc. Common Stock — how do they compare? Gerdau S.A. Common Stock trades at $5.15 (market cap $9.66B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.9× Gerdau S.A. Common Stock's market cap, and Gerdau S.A. Common Stock pays a 3.48% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| GGB | NTRA | |
|---|---|---|
Market Cap | $9.66B | $57.03B |
Volume | 9,572,970 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $5.18 | $425.64 |
52-Week Low | $3.25 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.61B | $56.18B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gerdau (GGB) trades at $5.18, up 0.78% with strong technical momentum and bullish moving average signals. The company reported mixed Q2 2026 earnings meeting expectations but missed previous quarters, while showing improved profitability with net income margin expanding to 3.23%. Recent news highlights institutional buying interest and dividend appeal, with the stock approaching its 52-week high of $5.48.
GGB presents a value opportunity with attractive valuation multiples (P/S 0.73, P/B 0.95) and strong analyst support (70% buy ratings). However, recent earnings misses and competitive pressures in Brazilian operations pose execution risks. The improving cash flow trajectory and institutional accumulation suggest potential upside if operational improvements continue.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
